Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience

Area of Science:

• Pharmacogenomics
• Immunology
• Infectious Diseases

Background:

• Abacavir hypersensitivity reactions (HSR) are a primary cause for treatment discontinuation.
• A strong correlation between HSR risk and ethnicity was observed.
• The human leukocyte antigen (HLA) B*5701 allele was identified as a key genetic predictor of abacavir HSR.

Purpose of the Study:

• To evaluate the impact of prospective HLA-B5701 screening on abacavir hypersensitivity rates.
• To assess the clinical utility of pharmacogenetic testing in managing abacavir therapy.

Main Methods:

• Prospective screening for the HLA-B5701 allele prior to abacavir initiation.
• Monitoring of hypersensitivity reactions in patients receiving abacavir.
• Comparison of hypersensitivity rates before and after implementation of HLA-B5701 screening.

Main Results:

• Prospective HLA-B5701 screening led to a significant reduction in abacavir hypersensitivity rates.
• The implementation of genetic testing effectively minimized early drug discontinuation due to HSR.
• No major adverse events were associated with the screening process itself.

Conclusions:

• Prospective HLA-B5701 screening is a highly effective strategy to prevent abacavir hypersensitivity.
• Pharmacogenetic testing should be standard practice for patients initiating abacavir therapy.
• This approach improves treatment adherence and patient safety in HIV management.